KIDNEY TRANSPLANTATION IN HIGHLY SENSITIZED PATIENTS
Clinical trials for KIDNEY TRANSPLANTATION IN HIGHLY SENSITIZED PATIENTS explained in plain language.
Never miss a new study
Get alerted when new KIDNEY TRANSPLANTATION IN HIGHLY SENSITIZED PATIENTS trials appear
Sign up with your email to follow new studies for KIDNEY TRANSPLANTATION IN HIGHLY SENSITIZED PATIENTS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Breakthrough drug may give hope to kidney patients rejected for transplant
Disease control CompletedThis study tested a drug called imlifidase in 113 highly sensitized kidney patients who had a positive crossmatch against a deceased donor. The drug was given before transplant to reduce the risk of rejection. The main goal was to see how many patients still had a working kidney …
Matched conditions: KIDNEY TRANSPLANTATION IN HIGHLY SENSITIZED PATIENTS
Phase: PHASE3 • Sponsor: Hansa Biopharma AB • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Breakthrough drug could open door to kidney transplants for 'Impossible' patients
Disease control CompletedThis phase 3 trial tested a drug called imlifidase in 64 highly sensitized kidney transplant patients who had almost no chance of finding a compatible donor. The drug breaks down harmful antibodies, allowing a transplant from a donor that would normally be rejected. The study mea…
Matched conditions: KIDNEY TRANSPLANTATION IN HIGHLY SENSITIZED PATIENTS
Phase: PHASE3 • Sponsor: Hansa Biopharma AB • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC